Skip to main content
. Author manuscript; available in PMC: 2023 Apr 5.
Published in final edited form as: Mol Aspects Med. 2021 Dec 14;83:101043. doi: 10.1016/j.mam.2021.101043

Fig. 6.

Fig. 6.

Nano-formulations of cisplatin, paclitaxel, and doxorubicin which are either FDA approved or under clinical trials for various malignancies. Information collected from U.S. National Library of Medicine, Clinicaltrial.gov.